A Novel Peptide Strategy to Prevent Surface-Triggered Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Adam Hansen et al, adding:
”Peptide-mediated inhibition of surface-initiated thrombogenesis
A designed peptide, P12, blocked thrombus formation triggered by artificial surfaces while leaving normal clotting intact.
In testing, it curbed surface-initiated thrombogenesis without impairing physiological hemostasis.
The authors see translational promise for treating device-related thrombosis and for engineering antithrombotic surfaces and coatings that resist clotting without raising bleeding risk.”
Title: Peptide-mediated inhibition of surface-initiated thrombogenesis
Authors: Adam Hansen, Bernard Essuman, Georgios Kementzidis, Nabila Jaman Tripti, Fubao Lin, Volodymyr Chernyshenko, Richard A.F. Clark, Yuefan Deng, Miriam Rafailovich, Dennis Galanakis
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM